Biotech

All Articles

Merck ceases period 3 TIGIT test in lung cancer cells for futility

.Merck &amp Co.'s TIGIT program has endured an additional setback. Months after shuttering a period ...

After a challenging year, Exscientia folds in to Recursion

.After a year specified through pipeline cuts, the departure of its chief executive officer and layo...

Cullinan, after $25M deal, hands back bispecific to Harbour

.Cullinan Therapy was actually excited sufficient with Harbour BioMed's bispecific invulnerable acti...

A deeper consider Intense Biotech's Intense 15

.In this week's incident of "The Best Line," we are actually diving right into Tough Biotech's yearl...

Lilly experiences stage 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's event celebrating the approval of Alzheimer's disease...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of considerable leadership hirings, firings as ...

Lykos will certainly inquire FDA to reexamine its own selection observing turndown of MDMA treatment for post-traumatic stress disorder

.Complying with a poor presenting for Lykos Therapies' MDMA candidate for post-traumatic stress diso...

AN 2 fifty percents census, stops period 3 trial after data dissatisfy

.AN2 Therapies is actually reassessing its company in response to lackluster midphase records, swear...

Merck pays out $700M for bispecific, snooping autoimmune position as well as opportunity to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 thousand ahead of time to challenge Amgen in a blood stream ...

Gilead spends J&ampJ $320M to leave licensing bargain for seladelpar

.With Gilead Sciences almost an FDA selection for its liver illness medicine seladelpar, the provide...